2014, Iroko Pharmaceuticals, Llc Therapeutic Developmental Pipeline for 2014

This report provides comprehensive information on the current therapeutic developmental pipeline of Iroko Pharmaceuticals, LLC’s Market, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Complete report is available @ http://www.reportsnreports.com/reports/279956-iroko-pharmaceuticals-llc-product-pipeline-review-2014.html

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Iroko Pharmaceuticals, LLC including business description, key information and facts, and its locations and subsidiaries

- The report reviews current pipeline of Iroko Pharmaceuticals, LLC’s human therapeutic division and enlists all their major and minor projects

- The report features product description and...